Long-term macrolides for non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis

Respirology

Volumn 19, Issue 3, 2014, Pages 321-329

  Wu, Qibiao ^a   Shen, Weixing ^b   Cheng, Haibo ^b   Zhou, Xiqiao ^c  

^a MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

bronchiectasis; efficacy; long term; macrolide; meta analysis

Indexed keywords

AZITHROMYCIN; INTERLEUKIN 8; MACROLIDE; ANTIINFECTIVE AGENT;

BRONCHIECTASIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPNEA; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; LUNG FUNCTION; LUNG LAVAGE; MACROPHAGE; META ANALYSIS; NEUTROPHIL COUNT; PATHOGEN CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPUTUM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TREATMENT DURATION; CYSTIC FIBROSIS; QUALITY OF LIFE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; CYSTIC FIBROSIS; FORCED EXPIRATORY VOLUME; HUMANS; MACROLIDES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84896317661     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12233     Document Type: Review

References (43)

1. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ,. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005; 128: 739-745.
2. King P, Holdsworth S, Freezer N, Holmes P,. Bronchiectasis. Intern. Med. J. 2006; 36: 729-737.
3. Smith MP,. Non-cystic fibrosis bronchiectasis. J. R. Coll. Physicians Edinb. 2011; 41: 132-139; quiz 139.
4. Weycker D, Edelsberg J, Oster G, Tino G,. Prevalence and economic burden of bronchiectasis. Clin. Pulm Med. 2005; 12: 205-209.
5. Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, Prevots DR,. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010; 138: 944-949.
6. Barker AF,. Bronchiectasis. N. Engl. J. Med. 2002; 246: 1383-1393.
7. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT,. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2012; 186: 657-665.
8. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R,. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur. Respir. J. 2009; 34: 843-849.
9. Roberts ME, Lowndes L, Milne DG, Wong CA,. Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis. Intern. Med. J. 2012; 42: e129-136.
10. Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65 (Suppl. 1): i1-58.
11. Cymbala AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, Victory JM, Amsden GW,. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat. Respir. Med. 2005; 4: 117-122.
12. Cameron EJ, McSharry C, Chaudhuri R, Farrow S, Thomson NC,. Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clin Exp Allergy. 2012; 42: 1302-1312.
13. Crosbie PAJ, Woodhead MA,. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur. Respir. J. 2009; 33: 171-181.
14. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M,. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am. J. Respir. Crit. Care Med. 1998; 157 (6 pt 1): 1829-1832.
15. Serisier DJ, Martin ML,. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir. Med. 2011; 105: 946-949.
16. Southern KW, Barker PM, Solis-Moya A, Patel L,. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 2012; (11): CD002203. Review.
17. Friedlander AL, Albert RK,. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010; 138: 1202-1212.
18. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K,. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur. J. Clin. Pharmacol. 2012; 68: 479-503.
19. Evans DJ, Bara A, Greenstone M,. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst. Rev. 2007; (2): CD001392.
20. Koh YY, Lee MH, Sun YH, Sung KW, Chae JH,. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur. Respir. J. 1997; 10: 994-999.
21. Tsang KW, Ho PI, Chan KN, Ip MS, Lam WK, Ho CS, Yuen KY, Ooi GC, Amitani R, Tanaka E,. A pilot study of low-dose erythromycin in bronchiectasis. Eur. Respir. J. 1999; 13: 361-364.
22. Elborn JS, Tunney MM,. Macrolides and bronchiectasis: clinical benefit with a resistance price. JAMA 2013; 309: 1295-1296.
23. Serisier DJ,. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med. 2013; 1: 262-274.
24. Higgins JPT, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. updated March 2011. The Cochrane Collaboration, 2011, West Sussex. [Accessed 10 Jul 2013.] Available from URL: www.cochrane-handbook.org
25. Juni P, Altman DG, Egger M,. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001; 323: 42-46.
26. Guyatt GH, Sackett DL, Cook DJ,. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1993; 270: 2598-2601.
27. Guyatt GH, Sackett DL, Cook DJ,. Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA 1994; 271: 59-63.
28. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ,. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 1996; 17: 1-12.
29. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP,. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-613.
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
31. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control. Clin. Trials 1986; 7: 177-188.
32. Dr Chris Cates' EBM web site. [Accessed 9 Jul 2013.] Available from URL: http://www.nntonline.net
33. Yalçin E, Kiper N, Ozçelik U, Doǧru D, Firat P, Sahin A, Ariyürek M, Mocan G, Gürcan N, Göçmen A,. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J. Clin. Pharm. Ther. 2006; 31: 49-55.
34. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG,. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013; 309: 1251-1259.
35. Liu JF, Zhong XN, He ZY, Zhong DJ, Bai J, Zhang JQ, Zhong W,. [ Impact of treatment with low dose roxithromycin on stable bronchiectasis ]. Zhonghua Jie He He Hu Xi Za Zhi 2012; 35: 824-827. (Article in Chinese).
36. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, Biga S, Schlebusch S, Dash P, Bowler SD,. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013; 309: 1260-1267.
37. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 660-667.
38. de Diego A, Milara J, Martinez E, Palop M, León M, Cortijo J,. Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis. Respirology 2013; 18: 1056-1062.
39. Macaskill P, Walter SD, Irwig L,. A comparison of methods to detect publication bias in meta-analysis. Stat. Med. 2001; 20: 641-654.
40. Kaptur N, Masters IB, Chang AB,. Exacerbations in non cystic fibrosis bronchiectasis: clinical features and investigations. Respir. Med. 2009; 103: 1681-1687.
41. Wilson CB, Jones PW, O'Leary C, Cole P, Wilson R,. Validation of the St.George's Respiratory Questionnaires in bronchiectasis. Am. J. Respir. Crit. Care Med. 1997; 158: 538-541.
42. Courtney JM, Kelly MG, Watt A, Garske L, Bradley J, Ennis M, Elborn JS,. Quality of life and inflammation in exacerbations of bronchiectasis. Chron. Respir. Dis. 2008; 5: 161-168.
43. Angrill J, Agustí C, De Celis R, Filella X, Rañó A, Elena M, De La Bellacasa JP, Xaubet A, Torres A,. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am. J. Respir. Crit. Care Med. 2001; 164: 1628-1632.